For the first time, in this paper, a well-established DSS-induced IBD model was used for the study of the temporal in situ expression profile of biomarkers; some of these are already well known and involved in the pathogenesis or therapy of human IBD, which are also highly clinically relevant to identify new biomarkers against which we can produce radiopharmaceuticals: TNF-α, α4β7, VEGFRII, GR-1, CD25, CD3, IL-12p40, IL-23R, IL-17A, IL-36R and F480. This evidence concerns the gene IL1RL2 and inflammatory bowel disease.